Lantheus Holdings logo

LNTH

Lantheus Holdings

$81.43

Earnings Summary

Revenue
$89.35Mn
Net Profits
$10.45Mn
Net Profit Margins
11.7%

Highlights

Revenue:

Lantheus Holdings’s revenue jumped 3.56% since last year same period to $89.35Mn in the Q4 2019. On a quarterly growth basis, Lantheus Holdings has generated 4.16% jump in its revenue since last 3-months.

Net Profits:

Lantheus Holdings’s net profit fell -21.39% since last year same period to $10.45Mn in the Q4 2019. On a quarterly growth basis, Lantheus Holdings has generated 115.2% jump in its net profits since last 3-months.

Net Profit Margins:

Lantheus Holdings’s net profit margin fell -24.09% since last year same period to 11.7% in the Q4 2019. On a quarterly growth basis, Lantheus Holdings has generated 106.6% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Lantheus Holdings post its latest quarter earnings

EPS Estimate Current Quarter
0.96
EPS Estimate Current Year
0.96

Highlights

EPS Estimate Current Quarter:

Lantheus Holdings’s earning per share (EPS) estimates for the current quarter stand at 0.96 - a 15.66% jump from last quarter’s estimates.

EPS Estimate Current Year:

Lantheus Holdings’s earning per share (EPS) estimates for the current year stand at 0.96.

Key Ratios

Key ratios of the Lantheus Holdings post its Q4 2022 earnings

Return on Assets (ROA)
0.02
Return on Equity (ROE)
0.06

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Lantheus Holdings’s return on assets (ROA) stands at 0.02.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Lantheus Holdings’s return on equity (ROE) stands at 0.06.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-02-25
0.01
0.07
600%
2020-04-30
0.27
0.36
33.33%
2020-11-05
0.01
0.04
300%
2020-07-31
0.06
0.1
66.67%

Company Information

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow™ serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.

Organisation
Lantheus Holdings
Headquarters
331 Treble Cove Road, North Billerica, MA, United States, 01862
Employees
698
Industry
Health Technology
CEO
Mary Heino